JPRN-UMIN000011065已完成3 期
Prophylaxis of febrile neutropenia by reducing chemotherapy-induced gastrointestinal mucosal injury - Prophylaxis of febrile neutropenia
Juntendo University School of Medicine0 个研究点目标入组 75 人开始时间: 2013年7月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6months-old 至 216months-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •patients with underlying infection before developping neutropenia patients who is allergic to probiotics or glutamine
研究者
相似试验
已完成
2 期
Garenoxacin to Prevent Febrile Neutropenia in Chemotherapy for Lung Cancerung cancerJPRN-UMIN000014711Institute of Biomedical Research and Innovation30
已完成
不适用
Preventing hospitalisation and early death from chronic heart failure in primary care: a randomised controlled trial of pharmacist led medication reviewCirculatory SystemChronic heart failureISRCTN70118765Greater Glasgow Primary Care NHS Trust (UK)2,400
已完成
不适用
Cohort Study on Febrile Neutropenia in Adjuvant Chemotherapy for Breast Cancer PatientsBreast CancerJPRN-UMIN000017857CSPOR-BC1,000
已完成
2 期
The study of fosaprepitant in the prevention of chemotherapy induced nausea and vomiting in patients with gynecologic cancer undergoing the combination therapy of Taxens and carboplatin.Cervical cancer, Endometrial cancer, Ovarian cancer, Fallopian tube cancer, and peritoneal cancerJPRN-UMIN000017804Saitama Medical University International Medical Center50
尚未招募
3 期
sing medicine Fosaprepitant along with other anti-vomiting medications for better control of vomiting and nausea in children receiving chemotherapyCTRI/2023/12/060941Cancer Institute (WIA)